Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

This study has suspended participant recruitment.

(the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has not yet been verified)

Sponsor:

Collaborator:

Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

Information provided by (Responsible Party):

WiSP Wissenschaftlicher Service Pharma GmbH

ClinicalTrials.gov Identifier:

NCT01088620

First received: March 16, 2010

Last updated: March 13, 2013

Last verified: March 2013

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has suspended participant recruitment.
Estimated Study Completion Date:	January 2014
Primary Completion Date:	January 2013 (Final data collection date for primary outcome measure)